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Background: Health-Related Quality of Life (HRQoL) is an important endpoint in oncology clinical trials aiming to
investigate the clinical benefit of new therapeutic strategies for the patient. However, the longitudinal analysis of
HRQoL remains complex and unstandardized. There is clearly a need to propose accessible statistical methods and
meaningful results for clinicians. The objective of this study was to compare three strategies for longitudinal
analyses of HRQoL data in oncology clinical trials through a simulation study.
Methods: The methods proposed were: the score and mixed model (SM); a survival analysis approach based on
the time to HRQoL score deterioration (TTD); and the longitudinal partial credit model (LPCM). Simulations
compared the methods in terms of type I error and statistical power of the test of an interaction effect between
treatment arm and time. Several simulation scenarios were explored based on the EORTC HRQoL questionnaires
and varying the number of patients (100, 200 or 300), items (1, 2 or 4) and response categories per item (4 or 7).
Five or 10 measurement times were considered, with correlations ranging from low to high between each
measure. The impact of informative missing data on these methods was also studied to reflect the reality of most
clinical trials.
Results: With complete data, the type I error rate was close to the expected value (5%) for all methods, while the
SM method was the most powerful method, followed by LPCM. The power of TTD is low for single-item dimensions,
because only four possible values exist for the score. When the number of items increases, the power of the SM
approach remained stable, those of the TTD method increases while the power of LPCM remained stable. With
10 measurement times, the LPCM was less efficient. With informative missing data, the statistical power of SM
and TTD tended to decrease, while that of LPCM tended to increase.
Conclusions: To conclude, the SM model was the most powerful model, irrespective of the scenario considered,
and the presence or not of missing data. The TTD method should be avoided for single-item dimensions of the
EORTC questionnaire. While the LPCM model was more adapted to this kind of data, it was less efficient than the
SM model. These results warrant validation through comparisons on real data.
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Health-Related Quality of Life (HRQoL) is an important
endpoint in oncology clinical trials aiming to investigate
the clinical benefit of new therapeutic strategies for the
patient and health care system [1]. However, the longitu-
dinal analysis of HRQoL remains complex and unstan-
dardized. To date, no recommendations have been made
on how to analyze longitudinal HRQoL data in oncology,
which is a key issue to facilitate comparison of results
between trials. Moreover, there is a clear need to propose
accessible statistical methods and meaningful results for
clinicians.
HRQoL is a subjective endpoint that is not directly ob-
servable, and it is therefore considered as a latent trait.
Patients’ HRQoL level is generally estimated by adminis-
tering validated questionnaires given to the patients at
different time points for a longitudinal approach.
In oncology clinical trials, one of the most widely used
questionnaires is the European Organization for Research
and Treatment of Cancer (EORTC) Quality of Life
Questionnaire (QLQ-C30), which is a validated, self-
administered questionnaire specific to cancer [2]. The
QLQ-C30 is a multidimensional questionnaire that
makes it possible to evaluate several HRQoL domains
(functional and symptomatic) specific to cancer. Each di-
mension is evaluated through one or more polytomous
items. A score is estimated for each dimension according
to specific scoring guidelines [3]. HRQoL questionnaires
are administered to the patients several times, depending
on the therapeutic setting: generally, at baseline (before
randomization), during treatment (e.g. at each chemother-
apy cycle), at the end of the study and/or repeatedly dur-
ing the follow-up until tumor progression or death. The
objective is to analyze the course of the patient HRQoL
over time. Given this longitudinal assessment, data are
often missing, particularly in the advanced or metastatic
settings [4].
Three types of missing data exist according to Little and
Rubin’s classification [5]. If the missing data are not
dependent on either past or present observed variables
(such as HRQoL level), then they are considered as miss-
ing completely at random (MCAR). For example, a patient
can forget to complete an item or a questionnaire at one
measurement time. Missing data are missing at random
(MAR) if they are not dependent on the present HRQoL
level, but can be explained by a previously observed vari-
able (previously observed HRQoL level or other clinical or
socio-demographic characteristic of the patient). For ex-
ample, the age of a patient may explain their reluctance to
answer a particular question. Finally, missing data are
missing not at random (MNAR) if they are dependent on
the present, unobserved HRQoL level. For example, if the
patient did not complete a questionnaire due to his/her al-
tered health status, it can reflect a deterioration of his/herHRQoL level. MCAR and MAR missing data are non-
informative and thus may not induce a bias in the analysis.
In contrast, the MNAR profile corresponds to informative
data and can bias the results if it is not adequately taken
into account in the longitudinal analysis method. In oncol-
ogy clinical trials and especially in advanced cancers, miss-
ing data are most often MNAR [6].
Missing data can be intermittent or monotone. Inter-
mittent missing items correspond to patients who fail
to complete one or more items in a given questionnaire
[7]. Entire forms may also be missing if the patient cannot
fill out the HRQoL questionnaire at a given measurement
time (intermittent missing form) [8]. In both these cases,
the patient will complete another questionnaire and re-
mains present in the study, since other HRQoL data are
available for that patient after the occurrence of this
intermittent missing data. Conversely, when a patient
drops out of the study prematurely, generally due to a
deterioration of health state or death, this corresponds
to monotone missing data [9]. In this case, no further
data are available after the patient drops out. The risk of
this situation is that only patients with the highest
HRQoL level be will analyzed. The impact of missing
data in longitudinal analysis has often been explored in
previous studies [10].
The longitudinal analysis of HRQoL data is generally
performed according to the Classical Test Theory (CTT).
In the CTT, the score constructed from the item answers
is considered as a good representation of the “true”
HRQoL level. Therefore, longitudinal analysis is based on
this score, considering that it is a semi-quantitative meas-
ure, even if only one item is used to construct the score.
Item Response Theory (IRT) is another approach, in
which items play a key role [11]. IRT models link the item
responses to the latent trait by a probabilistic model, gen-
erally with a logistic link. An important class of IRT
models is the Rasch-family models [12].
Some previous simulation studies have compared CTT
and IRT approaches for the longitudinal analyses of
patient-reported outcomes such as HRQoL [13-16].
These studies highlighted the similar performance of
both approaches in the context of complete data [13]
and in the presence of monotone missing data [14]. In
the presence of informative intermittent missing data,
the Rasch-family models seem to be more efficient than
CTT and, in particular, provide high statistical power
[15]. However, all these studies were performed on di-
chotomous items and restricted to three measurement
times. Dichotomous items are rarely used in HRQoL
questionnaires. The EORTC HRQoL questionnaires,
like most other HRQoL questionnaires, are built on a
Likert scale with polytomous items. Moreover, in oncol-
ogy clinical trials, more than three measurement times
are generally planned. Therefore, there exists a pressing
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polytomous items with more than three measurement
times. These previous simulation studies also focused
on the effects of time or treatment arm [13-16]. In ran-
domized clinical trials, HRQoL level is supposed to be
equal in both treatment arms at baseline. To detect a dif-
ferent effect, we investigate whether there is a significant
difference between arms in HRQoL over time, using an
interaction parameter between treatment arm and time.
While the interaction between time and treatment has
often been explored on real data in oncology clinical trials
[17], it has never been investigated in longitudinal HRQoL
simulations, to the best of our knowledge.
In previous studies, the CTT-based approach evaluated
was the score and mixed model (SM). This method is the
most widely used for longitudinal analyses. However, in
oncology clinical trials, a time to event approach, i.e. the
so-called time to HRQoL score deterioration (TTD) has
come to be used extensively [18-21]. This method has the
advantage of producing meaningful results for clinicians
as compared to IRT models, and more generally, mixed
models. No study to date has compared TTD to SM and
IRT models.
In this context, the objective of this study was to com-
pare, through a simulation study, three statistical methods
for analyzing longitudinal HRQoL data in oncology clin-
ical trials, namely:
– two CTT-based approaches, namely the SM model
and the TTD approach;
– and a longitudinal IRT model for polytomous items
called the Longitudinal Partial Credit Model
(LPCM).
Simulations compared the methods in terms of type I
error rate and statistical power of the test for an inter-
action effect between treatment arm and time. To reflect
the reality of most clinical trials, the impact of inform-
ative missing data on these methods was also studied,
with the implementation of both intermittent and mono-
tone missing data, depending on the patients’ HRQoL
level (MNAR profile).Methods
Longitudinal analysis models for health-related quality
of life
Score and mixed model
In CTT, the observed score is considered to be closed
to the real HRQoL level, i.e. the relationship between
the observed score and the “true” score is linear.
The SM model, based on the CTT approach, involves
applying a linear mixed model to the observed HRQoL
scores computed at each measurement time.We considered a model with two fixed effects: an inter-
action effect between the treatment arm and time (difference
in HRQoL changes between both treatments); and a time
effect (course of HRQoL over time). Moreover, we added
a random effect on patient (individual deviance from
average intercept) and time (individual deviance from
average time effect) with an unstructured covariance
matrix. The formula of the model considered is given in
Additional file 1. Random effects models give unbiased re-
sults in case of MAR. For MNAR, pattern mixture models
can be used [22].
Parameters were estimated using the Maximum Likeli-
hood method, which is based on the Newton–Raphson al-
gorithm. The model was implemented using SAS software
version 9.3 (SAS Institute Inc., Cary, NC, USA) with
PROC MIXED.
Time to health-related quality of life score deterioration
The TTD approach is also based on the observed score
and relies on the definition of the minimal clinically
important difference (MCID) in order to be effective
from a clinical point of view. Several definitions of
TTD have been proposed according to the therapeutic
situation and cancer site. Events can be defined accord-
ing to the chosen reference score, MCID, missing
scores, including all-cause death or not. Given the multi-
plicity of possible definitions of TTD, a standardization
of the longitudinal analysis of HRQoL data in oncology
according to the TTD approach has been proposed
[23]. Accordingly, four main definitions have been
retained in the present paper, in conformity with these
recommendations.
The most intuitive definition of the TTD is the time
from inclusion-randomization in the study to a first de-
terioration of at least one MCID unit as compared to
baseline score [24]. Patients with no deterioration before
their drop-out are censored at the time of the last HRQoL
assessment.
The observed deterioration can be definitive or not. In
the palliative setting, it is more relevant to study the
time until definitive HRQoL score deterioration (TUDD).
TUDD reflects the deterioration of the patient’s health
status (which is stable over time) and represents an ab-
sorbing state. TUDD has been defined as the time from
inclusion-randomization in the study to a first deterior-
ation of at least one MCID unit as compared to the
baseline score, with no further improvement of more
than one MCID unit as compared to baseline, or if the
patient drops out after deterioration, resulting in miss-
ing data [18].
In the published definitions, the reference score is
the baseline score. However, other scores can be chosen
as a reference, such as the best previous score. Indeed, the
baseline score is not necessarily the reference score for the
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standard, illustrating one component of a response shift
effect [23,25,26]. Therefore, both options were retained in
order to study their impact on this approach.
Regarding the EORTC HRQoL questionnaires, a 5-point
deterioration in HRQoL scores is generally considered as
the MCID [27]. The MCID was thus fixed at 5 points.
Table 1 summarizes the four definitions of TTD/TUDD
retained in our study.
Furthermore, a high score corresponds to a high level
of functioning on a functional scale, but corresponds to
strong presence of symptoms for a symptomatic scale.
Therefore, “deterioration” was defined as a decrease on
the functional scale or global health status dimension,
and as an increase on the symptomatic scale.
In the basic TTD/TUDD approach, intermittent missing
data were ignored, and we considered that the patient’s
HRQoL level remained unchanged since the last available
HRQoL assessment.
The TTD and TUDD estimations were calculated using
the Kaplan-Meier method [28].
These definitions of TTD and TUDD were implemented
using SAS software.Longitudinal mixed partial credit model
An important family of IRT models is the Rasch-family
models. Despite the interesting properties of these models,
such as specific objectivity, they are still rarely applied for
the longitudinal analysis of HRQoL data. To date, few in-
vestigations are ongoing using this technique in clinical
oncology [29,30].
The Partial Credit Model (PCM) is a Rasch-family
model adapted to polytomous items [31]. The PCM
models the probability that one individual n will choose
the response category k among the mj possible responses
for the item j (i.e. generalized linear mixed model with a
multinomial logit link function) given the latent trait θnTable 1 Summary of the definitions of time to quality of
life score deterioration approach retained for the
simulation study
MCID 5-point Reference score Deterioration
TTD≥ 5-points Baseline Not definitive
TUDD≥ 5-points with no further
improvement 5 points as compared
to reference score
Baseline Definitive
TTD≥ 5-points Best previous score Not definitive
TUDD≥ 5-points with no further
improvement 5 points as compared
to reference score and
Best previous score Definitive
MCID: Minimal Clinically Important Difference.
TTD: Time To Deterioration.
TUDD: Time Until Definitive Deterioration.and the category difficulty parameters δj;1;…; δj;mj for the
item j (see Additional file 1 for the formula).
As with all Rasch-family models, the PCM relies on
three fundamental assumptions, namely unidimensionality
of the latent trait, monotonicity and local independence of
the items conditionally to the latent trait.
In this study, a longitudinal extension of the PCM to
mixed-effect regression models was used and called the
Longitudinal PCM (LPCM).
Regarding this model, we considered a model with
two fixed effects; namely an interaction between treat-
ment and time; and a time effect. Moreover, we added
a random effect on patient and time with an unstruc-
tured covariance matrix (see Additional file 1 for the
formula).
This model was implemented using SAS software, using
PROC NLMIXED.Simulation algorithm
Complete data
The complete datasets were simulated in two steps.
The first step corresponded to the simulation of the la-
tent trait θn (θ1, θ2, θ3, θ4, θ5)′ for 5 measurement times,
for example, and for n = 1,…, N patients. This simulation
was performed for each treatment arm (0/1) with N/2 pa-
tients per arm. The latent trait followed a multivariate
normal distribution N5 (μ
0, Σ) with mean μ0 = (μ1, μ2, μ3,
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In the first-order autoregressive matrix, the correlation be-
tween HRQoL measures was assumed to decrease over
time [13-15]. We fixed σ2 = 1. For the experimental arm (1),
the latent trait was assumed to follow a multivariate normal
distribution N5 (μ
1, Σ) with mean μ1 = μ0 +Δ and with the
same covariance matrix. Δ represented the treatment arm
effect. In case of no treatment arm effect, Δ =0, otherwise
Δ ≠ 0.
The second step of the complete dataset simulation
corresponded to the determination of the item an-
swers. The patients’ responses to the items were ob-
tained with a LPCM in order to respect the three
assumptions of the Rasch-family models [32]. Category
difficulty parameters were fixed to estimated standard
normal-distribution quantiles and were similar for all
items.
Several simulations scenarios were explored based on
the EORTC HRQoL questionnaires [2] and with varia-
tions in the number of patients (100, 200 or 300), items
(1, 2 or 4) and response categories per item (4 or 7).
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follows:
– δ1 = −0.7; δ2 = 0 and δ3 = 0.7 for items with 4
response categories,
– δ1 = −1; δ2 = −0.6; δ3 = −0.2; δ4 = 0.2; δ5 = 0.6 and δ6
= 1 for items with 7 response categories.
The simulations were performed with 4 or 7 response
categories per item in order to reflect the construction
of the EORTC HRQoL questionnaires [2]. Simulations
with 7 response categories per item were only performed
with 2 items to illustrate the Global Health Status di-
mension of the QLQ-C30 questionnaire and only with
200 patients.
At each measurement time, a score was then computed
for each patient according to the recommendations of the
EORTC HRQoL questionnaires for a symptomatic scale
or Global Health Status scale [3]. The score Yn of the n-th








 100r , with r as the difference between
the highest and the lowest possible response to the items.
Five or 10 measurement times were considered with a
weak (0.4), moderate (0.7) or strong (0.9) correlation be-
tween each measure. Each scenario was simulated with a
time effect equal to:
– μ0 = (-0.4 -0.2 0 0.2 0.4) for 5 measurement times, and
– μ0 = (-0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4 0.5) for 10
measurement times.
As the mean of the latent trait increased over time,
we considered that the score observed corresponded
to a symptomatic scale. In this way, in the TTD ap-
proach, the deterioration was observed when the score
increased.
Each scenario was performed with a treatment arm effect
(Δ ≠ 0) or not (Δ =0). Different treatment arm effects were
tested and we retained the following effects:
– Δ1 = 0 for the first measurement time t = 1,
– Δt = 0.4, ∀ t > 1.
Generation of missing data
Simulations were then repeated with missing data gener-
ated from the complete datasets.
Only simulation of an MNAR profile was performed,
i.e. whereby patients with lower HRQoL levels were
more likely to present missing data [33]. The complete
algorithm for generating missing data is presented in
Additional file 2. In order to reflect the reality of most
clinical trials, both intermittent and monotone missing
data were simulated.For datasets with 5 measurement times:
– intermittent missing data were simulated on the
second and third times
– and monotone missing data on the fourth and fifth
times.
For datasets with 10 measurement times:
– intermittent missing data were simulated from the
second to the sixth measure
– and monotone missing data from the seventh to the
tenth measure.
In both cases, no missing data were generated at baseline.
Two types of intermittent missing data were considered:
intermittent missing forms and intermittent missing
items. Regarding intermittent missing forms, simula-
tion of missing data was performed at each measure-
ment time: if patient i presents missing data at time t,
then all items of the dimension are missing for that pa-
tient at time t. For CTT-based methods (SM and TTD),
simple imputation of missing items was performed by
using the mean of the answered items, provided at least
half of the items were answered by the patient, in ac-
cordance with the recommendation of the EORTC
HRQoL questionnaires (personal mean score) to esti-
mate the score.
Analyses were first conducted with both intermittent
missing forms and drop-out, and then with intermittent
missing items and drop-out. Analyses were conducted
with a proportion π(t) of missing data at each measure-
ment time t equal to 10%, 20% or 30%.Criteria for comparing the statistical methods
The type I error rate was estimated under the null hypoth-
esis H0 of the absence of a treatment arm effect (Δ =0). It
was calculated as the proportion of rejection of H0 under
the null hypothesis.
The statistical power of the test of an interaction effect
between treatment arm and time was estimated under
the alternative hypothesis H1 of the presence of a treat-
ment arm effect (Δ1 = 0; Δt = 0.4, ∀ t > 1). It was calculated
as the proportion of rejection of H0 under the alternative
hypothesis H1. The Wald and log-rank tests were used re-
spectively for mixed models and survival analyses based
on the TTD to test the rejection of the null hypothesis.
Each scenario was simulated 500 times in order to have
accurate estimations of the type I error rate and statistical
power.
In order to clarify all the scenarios investigated, the pa-
rameters and their corresponding values are summarized
in Table 2.
Table 2 Summary of the parameters used in the
simulation study and the corresponding values
Parameters Values
Number of time points 5 or 10
Time effect Linear: μ0 =−0.4 and μend=−0.4
Arm effect Δ = 0 for T≥ T0 or Δ = 0 at T0;




Number of Patients 100; 200; 300
Items 1; 2; 4
Response Categories per item 4; 7 (only for 2 items, 200 patients)
Percentage of missing data
at each follow-up
0; 10%; 20%; 30%
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Complete data
With complete data, the type I error rate was close to
the expected value (5%) for all methods (Table 3). The
SM method was the most powerful method, irrespective
of the parameter values in each scenario (Table 4). The
statistical power of the TTD/TUDD approach was low,
especially for single-item dimensions. The statistical
power of the LPCM was intermediate, falling between
that of the SM and that of the TTD/TUDD approach.
For example, with N = 300 patients, I = 1 item, ρ = 0.4
and 5 measures, the power of the SM method, TTD vs
baseline (“TTD baseline”) and LPCM was around 93%,
22% and 92% respectively. When the number of items
increased, the statistical power of the SM approach
remained stable, those of TTD/TUDD approach in-
creased while the power of the LPCM remained stable.
For 10 measurement times, the LPCM method was less
powerful than for 5 measurement times. For example,
when N = 300 patients, I = 4 items, ρ = 0.7 and with 5
measurement times, the power of the LPCM method
was around 79%, while that of the SM method was
around 96%. With 10 measurement times and the same
value for all other parameters, the power of the LPCM
method decreased to 52% while that of the SM method
was around 99%. The power of the SM method and the
TTD/TUDD approaches increased for items with 7 re-
sponse categories as compared to those with 4 response
categories, while the power of LPCM decreased slightly.
When the correlation between measures increased, the
power of the SM method tended to decrease overall,
while that of the TTD/TUDD approach tended to in-
crease (although the power values remained low) and
the power of LPCM tended to decrease.
Incomplete data
With intermittent missing forms and drop-out, the type
I error rate was close to the expected value (5%) for allmethods, whatever the proportion of missing data (Table 5
and Table A1 in Additional file 3). The statistical power of
the test for an interaction between treatment arm and
time (Table 6 and Table A2 in Additional file 3) decreased
for the SM method and TTD/TUDD approaches, except
for TUDD as compared to the best previous score
(“TUDD best”). With 30% missing data as compared to
complete case data, 5 measurement times, N = 200 pa-
tients, I = 4 items, ρ = 0.7, statistical power decreased from
81% to 76% for SM method, from 55% to 40% for “TTD
baseline”, from 39.4% to 28.4% for “TTD best” and from
46% to 39% for “TUDD baseline”.
Regarding TUDD, as compared to the best previous
score (“TUDD best”), statistical power generally increased.
With 30% missing data as compared to complete case
data, with 5 measurement times, N = 300 patients, I = 4
items, ρ = 0.7, the statistical power increased from 30% to
36% for TUDD as compared to the best previous score.
Regarding the LPCM method, the statistical power de-
creased or remained stable with 5 measurement times,
whereas it generally increased for 10 measurement times.
With 10 measurement times, N = 300 patients, I = 4 items,
ρ = 0.9, the statistical power of LPCM method increased
from 53% with complete data to 77% with 30% missing
data.
With intermittent missing items and drop-out, results
were close to those with intermittent missing forms and
drop out. The type I error rate still remained stable and
close to the expected value (5%) for all methods, what-
ever the proportion of missing data generated (see Table
A3 in Additional file 3). The statistical power of the test
of interaction between treatment arm and time (see
Table A4 in Additional file 3) slightly decreased for the
SM method and TTD/TUDD approaches, except for
TUDD as compared to the best previous score (“TUDD
best”), and regardless of the number of measurement
times, items, response categories per item ore correla-
tions between HRQoL measures. This trend was gener-
ally more pronounced than for intermittent missing
forms and drop out. With 30% missing data, 5 measure-
ment times, N = 200 patients, I = 4 items, ρ = 0.7, the
statistical power decreased from 81% to 72% for the SM
method, from 55% to 28% for “TTD baseline”, from 39%
to 20% for “TTD best” and from 46% to 28% for “TUDD
baseline”.
The statistical power of the LPCM method increased
with intermittent missing data. This trend was generally
more pronounced than for intermittent missing forms
and drop out. With 10 measurement times, N = 300 pa-
tients, I = 4 items, ρ = 0.9, the statistical power of the
LPCM method increased from 53% with complete data
to 78% with 30% missing data.
Figure 1 shows the statistical power for all methods
with complete data, intermittent missing forms and drop
Table 3 Type I error rate of the test of interaction between treatment arm and time, for simulations with complete
data


















100 1 4 0.4 0.056 0.076 0.062 0.062 0.068 0.068 0.042 0.058 0.046 0.070 0.060 0.100
0.7 0.048 0.028 0.058 0.052 0.060 0.048 0.032 0.050 0.066 0.042 0.040 0.044
0.9 0.062 0.032 0.040 0.056 0.048 0.064 0.044 0.066 0.054 0.056 0.076 0.046
2 4 0.4 0.062 0.058 0.048 0.056 0.064 0.056 0.054 0.046 0.042 0.046 0.060 0.050
0.7 0.048 0.064 0.064 0.056 0.062 0.048 0.048 0.058 0.048 0.052 0.064 0.044
0.9 0.054 0.054 0.054 0.050 0.044 0.066 0.040 0.066 0.058 0.056 0.056 0.036
4 4 0.4 0.080 0.062 0.070 0.064 0.072 0.070 0.052 0.048 0.060 0.070 0.064 0.046
0.7 0.078 0.040 0.048 0.052 0.068 0.072 0.048 0.060 0.060 0.050 0.064 0.052
0.9 0.078 0.046 0.046 0.056 0.060 0.070 0.042 0.048 0.056 0.068 0.048 0.046
200 1 4 0.4 0.038 0.050 0.046 0.046 0.040 0.054 0.068 0.052 0.048 0.072 0.050 0.138
0.7 0.056 0.064 0.042 0.054 0.062 0.054 0.054 0.052 0.064 0.054 0.054 0.058
0.9 0.040 0.034 0.052 0.058 0.048 0.034 0.034 0.038 0.036 0.042 0.042 0.046
2 4 0.4 0.046 0.060 0.048 0.046 0.042 0.046 0.044 0.064 0.064 0.068 0.054 0.048
0.7 0.054 0.072 0.072 0.074 0.060 0.054 0.032 0.054 0.050 0.048 0.044 0.046
0.9 0.068 0.054 0.060 0.046 0.046 0.066 0.040 0.044 0.058 0.058 0.044 0.042
7 0.4 0.040 0.036 0.046 0.034 0.046 0.040 0.050 0.056 0.040 0.062 0.054 0.054
0.7 0.044 0.046 0.050 0.056 0.056 0.040 0.038 0.066 0.058 0.056 0.054 0.042
0.9 0.062 0.046 0.052 0.054 0.042 0.056 0.042 0.058 0.040 0.060 0.054 0.040
4 4 0.4 0.042 0.056 0.050 0.052 0.060 0.036 0.048 0.032 0.056 0.052 0.046 0.042
0.7 0.044 0.050 0.060 0.052 0.052 0.052 0.038 0.052 0.058 0.058 0.066 0.056
0.9 0.054 0.042 0.050 0.052 0.042 0.050 0.030 0.054 0.048 0.064 0.054 0.042
300 1 4 0.4 0.046 0.054 0.064 0.052 0.072 0.058 0.050 0.052 0.046 0.050 0.058 0.108
0.7 0.076 0.058 0.066 0.068 0.066 0.074 0.034 0.042 0.044 0.054 0.054 0.046
0.9 0.038 0.050 0.040 0.050 0.052 0.034 0.034 0.058 0.072 0.074 0.076 0.036
2 4 0.4 0.046 0.072 0.058 0.082 0.058 0.054 0.034 0.056 0.054 0.072 0.054 0.062
0.7 0.044 0.058 0.046 0.044 0.052 0.046 0.040 0.054 0.050 0.052 0.058 0.038
0.9 0.052 0.060 0.064 0.050 0.046 0.054 0.050 0.064 0.062 0.038 0.050 0.044
4 4 0.4 0.040 0.062 0.068 0.042 0.044 0.064 0.038 0.042 0.060 0.048 0.062 0.040
0.7 0.050 0.054 0.062 0.054 0.050 0.060 0.044 0.050 0.060 0.048 0.056 0.048
0.9 0.044 0.066 0.062 0.044 0.052 0.038 0.036 0.044 0.048 0.028 0.044 0.048
The methods compared are the Score and Mixed Model (SM), Longitudinal Partial Credit Model (LPCM), Time to HRQoL score deterioration as compared to the
baseline score (TTD baseline) or the best previous score (TTD best) and time until definitive deterioration of the HRQoL score as compared to the baseline score
(TUDD baseline) or the best previous score (TUDD best) for different values of sample size (N), items (I), response category per item (J) and correlations between
HRQoL measures (ρ).
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=200 patients, moderate correlation (ρ = 0.7) and 20%
missing data. The statistical power of the SM method and
TTD/TUDD approach remained stable or decreased for
incomplete data as compared to complete data, for I = 2
or 4 items, whatever the number of measurement times,
and particularly with intermittent missing item and drop-
out. For the same parameter values, the statistical power
of the LPCM method increased for incomplete data ascompared to complete data. For I = 1 item and 5 measure-
ment times, the statistical power of all methods remained
stable. For 10 measurement times, the statistical power
decreased in the presence of intermittent missing data for
the SM approach, whereas it increased for the TTD/
TUDD and LPCM approaches. Finally, this figure con-
firms that the SM method is the most powerful method,
regardless of the scenario considered and the presence or
not of missing data.
Table 4 Power of the test of interaction between treatment arm and time, for simulations with complete data


















100 1 4 0.4 0.518 0.118 0.102 0.130 0.100 0.472 0.784 0.134 0.132 0.120 0.058 0.654
0.7 0.418 0.148 0.104 0.156 0.126 0.388 0.578 0.114 0.110 0.118 0.082 0.484
0.9 0.404 0.148 0.124 0.174 0.142 0.380 0.414 0.124 0.126 0.130 0.084 0.352
2 4 0.4 0.590 0.182 0.146 0.218 0.138 0.528 0.874 0.172 0.158 0.192 0.080 0.726
0.7 0.488 0.214 0.162 0.208 0.162 0.432 0.628 0.188 0.180 0.192 0.096 0.354
0.9 0.414 0.226 0.150 0.216 0.134 0.394 0.466 0.206 0.164 0.210 0.096 0.290
4 4 0.4 0.680 0.260 0.168 0.204 0.128 0.412 0.916 0.236 0.190 0.246 0.090 0.396
0.7 0.550 0.290 0.214 0.246 0.148 0.394 0.664 0.282 0.228 0.258 0.116 0.214
0.9 0.496 0.394 0.290 0.364 0.210 0.428 0.428 0.400 0.284 0.314 0.150 0.228
200 1 4 0.4 0.812 0.212 0.162 0.240 0.142 0.778 0.970 0.140 0.168 0.182 0.060 0.858
0.7 0.644 0.208 0.168 0.204 0.148 0.622 0.872 0.170 0.184 0.216 0.066 0.798
0.9 0.644 0.234 0.176 0.256 0.160 0.612 0.670 0.194 0.152 0.204 0.082 0.572
2 4 0.4 0.894 0.296 0.232 0.304 0.148 0.830 0.992 0.272 0.246 0.328 0.116 0.952
0.7 0.760 0.350 0.262 0.344 0.214 0.678 0.934 0.326 0.242 0.334 0.114 0.618
0.9 0.720 0.416 0.324 0.440 0.276 0.710 0.726 0.398 0.316 0.400 0.156 0.494
7 0.4 0.936 0.346 0.270 0.328 0.214 0.832 0.999 0.362 0.324 0.366 0.096 0.900
0.7 0.826 0.468 0.392 0.458 0.284 0.678 0.926 0.444 0.358 0.360 0.124 0.458
0.9 0.810 0.580 0.442 0.614 0.400 0.788 0.726 0.600 0.506 0.536 0.218 0.458
4 4 0.4 0.954 0.402 0.292 0.364 0.156 0.722 0.996 0.370 0.288 0.366 0.118 0.672
0.7 0.812 0.552 0.394 0.456 0.236 0.606 0.934 0.484 0.362 0.380 0.142 0.368
0.9 0.796 0.678 0.518 0.632 0.388 0.760 0.728 0.608 0.510 0.494 0.196 0.374
300 1 4 0.4 0.928 0.218 0.180 0.274 0.160 0.916 0.998 0.202 0.236 0.234 0.062 0.920
0.7 0.842 0.274 0.234 0.282 0.162 0.842 0.974 0.232 0.220 0.242 0.082 0.920
0.9 0.820 0.338 0.248 0.386 0.234 0.796 0.856 0.244 0.236 0.300 0.108 0.772
2 4 0.4 0.980 0.410 0.336 0.446 0.232 0.948 0.998 0.390 0.342 0.424 0.092 0.988
0.7 0.918 0.494 0.366 0.514 0.304 0.858 0.984 0.500 0.378 0.462 0.124 0.788
0.9 0.902 0.560 0.418 0.594 0.366 0.886 0.902 0.508 0.388 0.476 0.154 0.670
4 4 0.4 0.990 0.578 0.416 0.510 0.242 0.856 0.998 0.560 0.398 0.486 0.172 0.822
0.7 0.956 0.636 0.488 0.564 0.302 0.792 0.990 0.678 0.526 0.582 0.194 0.516
0.9 0.966 0.820 0.678 0.790 0.484 0.916 0.912 0.834 0.650 0.708 0.300 0.530
The methods compared are the Score and Mixed Model (SM), Longitudinal Partial Credit Model (LPCM), Time to HRQoL score deterioration as compared to the
baseline score (TTD baseline) or the best previous score (TTD best) and time until definitive deterioration of the HRQoL score as compared to the baseline score
(TUDD baseline) or the best previous score (TUDD best) for different values of sample size (N), items (I), response category per item (J) and correlations between
HRQoL measures (ρ).
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In order for HRQoL to be recognized as a major endpoint
in oncology clinical trials to qualify for the patient the
clinical benefit of a new therapeutic strategy, guidelines
for longitudinal analyses are required. Three main methods
can be proposed to analyze longitudinal HRQoL data,
namely the SM method; a time-to-event approach based
on the TTD; and the LPCM approach. This study is the
first to compare these techniques for longitudinal analysis
of HRQoL data, with polytomous items and more than
three measurement times. Moreover, our simulation studyis the first to address the interaction effect between treat-
ment arm and time in the context of longitudinal HRQoL
data, which corresponds to the conditions of randomized
clinical trials with no group effect at baseline. Finally, both
intermittent and monotone missing data depending on
patients’ HRQoL level (MNAR profile) were studied,
thereby approaching the actual conditions of clinical trials.
The results obtained on complete data show that the
type I error rate was close to the expected value (5%) for
all methods. Moreover, the SM model was the most
powerful method to highlight an interaction between
Table 5 Type I error of the test of interaction between treatment arm and time, for datasets simulated with intermittent
missing forms and monotone missing data
5 measures 10 measures

















100 1 4 0.7 0.10 0.068 0.052 0.058 0.058 0.056 0.064 0.052 0.068 0.058 0.066 0.044 0.060
0.20 0.068 0.042 0.048 0.060 0.078 0.060 0.054 0.048 0.036 0.078 0.050 0.056
0.30 0.074 0.054 0.050 0.074 0.068 0.064 0.062 0.060 0.050 0.056 0.054 0.056
2 4 0.7 0.10 0.068 0.052 0.058 0.050 0.050 0.058 0.038 0.048 0.040 0.040 0.052 0.048
0.20 0.070 0.050 0.054 0.060 0.066 0.068 0.052 0.060 0.060 0.056 0.060 0.052
0.30 0.072 0.058 0.062 0.066 0.076 0.070 0.068 0.068 0.056 0.056 0.054 0.052
4 4 0.7 0.10 0.076 0.036 0.048 0.068 0.062 0.078 0.046 0.054 0.072 0.048 0.048 0.048
0.20 0.074 0.036 0.052 0.066 0.068 0.080 0.076 0.054 0.044 0.070 0.052 0.052
0.30 0.058 0.058 0.066 0.066 0.054 0.050 0.070 0.058 0.056 0.058 0.046 0.074
200 1 4 0.7 0.10 0.058 0.042 0.038 0.054 0.052 0.058 0.042 0.066 0.058 0.068 0.068 0.056
0.20 0.076 0.050 0.056 0.046 0.042 0.062 0.052 0.042 0.034 0.052 0.054 0.052
0.30 0.048 0.052 0.064 0.062 0.046 0.046 0.064 0.058 0.038 0.050 0.044 0.066
2 4 0.7 0.10 0.046 0.044 0.048 0.038 0.046 0.042 0.044 0.054 0.046 0.052 0.058 0.058
0.20 0.050 0.056 0.068 0.062 0.058 0.044 0.052 0.054 0.036 0.062 0.044 0.058
0.30 0.062 0.048 0.040 0.066 0.072 0.060 0.038 0.044 0.038 0.038 0.040 0.044
7 0.7 0.10 0.044 0.056 0.054 0.056 0.044 0.050 0.036 0.052 0.062 0.050 0.048 0.044
0.20 0.058 0.056 0.044 0.070 0.056 0.046 0.046 0.058 0.068 0.054 0.048 0.058
0.30 0.072 0.058 0.060 0.060 0.076 0.062 0.034 0.074 0.058 0.062 0.066 0.046
4 4 0.7 0.10 0.040 0.040 0.056 0.042 0.044 0.052 0.042 0.056 0.062 0.054 0.056 0.052
0.20 0.040 0.052 0.052 0.064 0.058 0.054 0.050 0.060 0.036 0.050 0.056 0.062
0.30 0.054 0.054 0.054 0.056 0.064 0.052 0.042 0.046 0.056 0.044 0.052 0.054
300 1 4 0.7 0.10 0.032 0.054 0.048 0.046 0.038 0.034 0.040 0.066 0.070 0.080 0.060 0.038
0.20 0.042 0.072 0.058 0.056 0.044 0.044 0.042 0.054 0.046 0.060 0.038 0.050
0.30 0.046 0.050 0.048 0.048 0.046 0.042 0.046 0.052 0.044 0.064 0.052 0.040
2 4 0.7 0.10 0.038 0.044 0.042 0.048 0.040 0.042 0.040 0.042 0.050 0.048 0.048 0.046
0.20 0.052 0.048 0.056 0.042 0.048 0.054 0.044 0.062 0.056 0.044 0.044 0.048
0.30 0.036 0.052 0.050 0.046 0.044 0.048 0.034 0.036 0.050 0.054 0.064 0.034
4 4 0.7 0.10 0.034 0.054 0.044 0.048 0.048 0.038 0.034 0.056 0.048 0.044 0.056 0.038
0.20 0.038 0.054 0.056 0.064 0.054 0.036 0.034 0.042 0.036 0.048 0.050 0.040
0.30 0.038 0.036 0.038 0.050 0.046 0.040 0.044 0.048 0.038 0.052 0.060 0.05
The methods compared are Score and Mixed Model (SM), longitudinal Partial Credit Model (LPCM), Time to HRQoL score deterioration as compared to the
baseline score (TTD baseline) or the best previous score (TTD best) and time until definitive deterioration of the HRQoL score as compared to the baseline score
(TUDD baseline) or the best previous score (TUDD best) for different values of sample size (N), items (I), response categories per item (J), correlations between
HRQoL measures (ρ) and proportion of missing data (π).
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TTD/TUDD approach, (whatever the definition of de-
terioration considered), was very low for single-item di-
mensions, even with a large sample size. This can be
explained by the fact that only four possible values exist
for the score. Indeed, we suggest that such an approach
be avoided for single-item dimensions, meaning that 6
of the 15 dimensions of the QLQ-C30 questionnaire are
concerned by this caveat. The statistical power of the
LPCM was close to those of the SM model for 5measurement times, but decreased for scenarios with 10
measurement times. The statistical power of the differ-
ent methods compared was also influenced by the level
of correlation between HRQoL measures (ρ parameter).
When the correlation increased, the statistical power of
the SM and LPCM methods generally decreased,
whereas those of the TTD/TUDD approach increased,
regardless of the value of the other parameters. The cor-
relation between HRQoL measures was strong if the pa-
tient’s HRQoL level at one time could accurately predict
Table 6 Power of the test of interaction between treatment arm and time, for datasets simulated with intermittent
missing forms and monotone missing data
5 measures 10 measures

















100 1 4 0.7 0.10 0.396 0.124 0.100 0.140 0.102 0.366 0.568 0.118 0.130 0.108 0.094 0.502
0.20 0.358 0.098 0.088 0.134 0.104 0.336 0.534 0.100 0.094 0.128 0.058 0.478
0.30 0.342 0.126 0.092 0.120 0.088 0.318 0.490 0.134 0.098 0.146 0.094 0.430
2 4 0.7 0.10 0.474 0.224 0.168 0.208 0.144 0.414 0.596 0.170 0.150 0.182 0.054 0.380
0.20 0.446 0.206 0.164 0.192 0.136 0.402 0.560 0.182 0.136 0.200 0.086 0.400
0.30 0.404 0.160 0.142 0.162 0.132 0.370 0.506 0.148 0.126 0.192 0.094 0.376
4 4 0.7 0.10 0.520 0.266 0.214 0.252 0.172 0.380 0.652 0.264 0.210 0.220 0.124 0.258
0.20 0.514 0.256 0.190 0.248 0.164 0.406 0.626 0.274 0.188 0.262 0.132 0.286
0.30 0.462 0.232 0.174 0.224 0.160 0.344 0.580 0.216 0.164 0.210 0.116 0.306
200 1 4 0.7 0.10 0.652 0.208 0.160 0.202 0.162 0.630 0.838 0.146 0.168 0.174 0.076 0.774
0.20 0.644 0.206 0.178 0.218 0.162 0.626 0.810 0.212 0.190 0.216 0.114 0.740
0.30 0.634 0.222 0.136 0.208 0.146 0.616 0.764 0.156 0.142 0.202 0.108 0.716
2 4 0.7 0.10 0.754 0.318 0.236 0.332 0.186 0.690 0.902 0.316 0.244 0.280 0.082 0.650
0.20 0.748 0.346 0.226 0.378 0.218 0.692 0.850 0.352 0.274 0.322 0.116 0.632
0.30 0.682 0.280 0.212 0.320 0.212 0.644 0.818 0.282 0.204 0.292 0.146 0.678
7 0.7 0.10 0.816 0.452 0.348 0.456 0.294 0.72 0.92 0.472 0.338 0.412 0.124 0.478
0.20 0.784 0.448 0.328 0.416 0.278 0.666 0.924 0.424 0.308 0.408 0.154 0.554
0.30 0.786 0.394 0.254 0.404 0.260 0.71 0.862 0.438 0.29 0.374 0.170 0.616
4 4 0.7 0.10 0.812 0.470 0.334 0.412 0.248 0.652 0.910 0.462 0.366 0.392 0.156 0.434
0.20 0.816 0.468 0.316 0.402 0.216 0.686 0.890 0.442 0.314 0.386 0.174 0.482
0.30 0.762 0.396 0.284 0.390 0.266 0.652 0.862 0.422 0.266 0.412 0.164 0.522
300 1 4 0.7 0.10 0.842 0.320 0.254 0.336 0.212 0.822 0.956 0.202 0.226 0.252 0.114 0.910
0.20 0.820 0.286 0.224 0.294 0.196 0.800 0.926 0.236 0.208 0.284 0.138 0.888
0.30 0.756 0.266 0.214 0.278 0.198 0.736 0.910 0.276 0.192 0.290 0.144 0.886
2 4 0.7 0.10 0.914 0.458 0.322 0.454 0.284 0.858 0.980 0.432 0.328 0.436 0.114 0.802
0.20 0.890 0.400 0.278 0.434 0.260 0.858 0.964 0.416 0.274 0.418 0.166 0.836
0.30 0.862 0.416 0.302 0.442 0.262 0.818 0.944 0.450 0.268 0.432 0.196 0.830
4 4 0.7 0.10 0.964 0.660 0.456 0.618 0.324 0.846 0.992 0.636 0.480 0.538 0.200 0.596
0.20 0.932 0.626 0.430 0.580 0.338 0.834 0.980 0.606 0.400 0.560 0.236 0.646
0.30 0.934 0.574 0.386 0.572 0.364 0.856 0.972 0.598 0.376 0.562 0.246 0.724
The methods compared are the Score and Mixed Model (SM), longitudinal Partial Credit Model (LPCM), Time to HRQoL score deterioration as compared to the
baseline score (TTD baseline) or the best previous score (TTD best) and time until definitive deterioration of the HRQoL score as compared to the baseline score
(TUDD baseline) or the best previous score (TUDD best) for different values of sample size (N), items (I), response categories per item (J), correlations between
HRQoL measures (ρ) and proportion of missing data (π).
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closely spaced measures, i.e. some intensive HRQoL
measures, as for clinical trials where there is rapid
change in the patient’s health status. Conversely, a weak
correlation between HRQoL measures could correspond
to more distant measures, reflecting a cohort study
design.
With intermittent missing data (missing items or miss-
ing forms) and drop-out, the type I error rate remained
closed to the expected value for all statistical methods,whatever the proportion of missing data and the sce-
nario considered. The statistical power generally de-
creased for the SM and TTD/TUDD approaches, except
for TUDD as compared to the best previous score. For
this definition, the statistical power generally increased
or remained stable with the simulation of missing data.
This could be explained by the simulation of missing
data depending on HRQoL level, i.e. patients with a low
HRQoL level were more likely to present missing data.
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Figure 1 (See legend on next page.)
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Figure 1 Power of the test of interaction between treatment arm and time for complete datasets (CD), datasets with intermittent
missing forms and monotone missing data (IMF), and datasets with intermittent missing items and monotone missing data (IMI). The
methods compared are the Score and Mixed Model (SM), longitudinal Partial Credit Model (LPCM), Time to HRQoL score deterioration as compared to
the baseline score (TTD baseline) or the best previous score (TTD best) and time until definitive deterioration of the HRQoL score as compared to the
baseline score (TUDD baseline) or the best previous score (TUDD best) for different values of sample size (N), items (I), correlations between HRQoL
measure (ρ) and the proportion of missing data, which was fixed at π = 0.20.
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and this improvement would represent the new refer-
ence score for “TUDD best”. Thus, a small deterioration
of at least 5 points compared to this new reference score
was not considered as a deterioration as compared to
the baseline score. Finally, this deterioration was more
likely to be followed by monotone missing data, involv-
ing a definitive deterioration as compared to the best
previous score.
The same trends were observed for all methods re-
garding statistical power, whatever the type of missing
data considered (intermittent missing items or missing
forms). However, the statistical power decreased more
for the SM and TTD/TUDD approaches in the presence
of intermittent missing items than when there were
intermittent missing forms. For analyses with intermit-
tent missing items, the score could be estimated if at
least 50% of the items had been answered, and on the
assumption that missing items are not informative of the
patient’s HRQoL level. This could result in an overesti-
mation or underestimation of the patient’s HRQoL level,
which could induce a bias in the longitudinal analysis.
As highlighted in other studies [14,15], these results
emphasize the limitations of the personal mean score
imputation method, despite the fact that it is the most
commonly used technique for computing scores. Indeed,
it should be avoided, particularly when the proportion of
missing data is high. Regarding the LPCM method, the
statistical power increased more in the presence of inter-
mittent missing items than when there were intermittent
missing forms. This is due to the specific objectivity
property of Rasch-family models, which can highly ac-
curately estimate the latent trait (i.e. HRQoL), even with
few items answered [12]. This is because a minimum in-
formation is provided (at least one item is answered),
whereas with missing forms, no information is available
for IRT models. Moreover, it seems that the LPCM is
more powerful with few measurement time points, since
the LPCM has greater power with 5 than with 10 meas-
urement times. Thus, when missing data were generated,
the statistical power of LPCM increased.
Previous studies comparing score-based approaches
with a Rasch-based approach have highlighted the similar
performance of the SM and longitudinal Rasch models in
case of complete data [13] and in the presence of mono-
tone missing data [14]. These studies also showed thatRasch-family models seem to be more efficient than SM
models in the presence of informative intermittent miss-
ing data [15]. In our study, we also highlight that the stat-
istical power of the IRT models was less affected by the
presence of missing data than those of the SM method.
However, contrary to previous published studies, the SM
method was generally more powerful in our study than
the IRT model for both complete and incomplete data
with informative missing data, and particularly with 10
measurement times. The good results of the SM model
could be explained by a bias from fixed effect estimations,
since there are several data characteristics that the SM
model does not take into account, such as the ceiling and
floor effects, or asymmetric data [34,35]. It is also import-
ant to note that the SM method generally required the
normality of the score studied, which cannot be respected
for single-item scales of the QLQ-C30 questionnaire with
only 4 possible values for the scores. These discrepancies
with the literature may also be partly due to the number
of measurement times considered. The IRT models seem
to be less powerful when the number of measurement
times is high. Moreover, in previous studies, researchers
chose to proceed in two steps to construct the longitu-
dinal IRT model, namely estimation of the item parame-
ters and HRQoL latent trait for each person at each time
in a first step, and then modeling of the link between the
latent trait and the time using a linear mixed model. Our
design integrated at least five measures, thereby reflecting
a longitudinal design, similar to that used in clinical trials.
Moreover, polytomous items were used in our research,
whereas dichotomous items were used in previous studies.
Finally, we investigated the interaction between treatment
arm and time in our study, whereas previous studies ana-
lyzed only the time effect [13-15] or the group effect [16].
It therefore appears crucial to pursue research in this area
to test the ability of these models in the context of polyto-
mous items.
In our study, both linear and non-linear mixed models
and time to event analysis were compared. The time
to event (i.e. “survival”) approach based on the time to
HRQoL score deterioration is relevant in the event of
a quicker alteration of patients’ HRQoL in one treat-
ment arm as compared to the other, and if this differ-
ence is maintained over time (risk proportionality).
Therefore, the absence of an arm effect at baseline is
coherent.
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ideal but theoretical - considering that items were derived
from an IRT model and that the corresponding symptom-
atic scale followed a multivariate normal distribution with
an auto-regressive covariance matrix. It is necessary to
simulate the data using an IRT model in order to guaran-
tee that the fundamental assumptions of the model are
respected, as recommended by Holland et al. [32]. Since
the parameters of the IRT model are re-estimated, it can-
not necessarily bias the results in favor of the IRT model.
Nevertheless, it corresponds to an ideal situation that does
not reflect real data when the HRQoL questionnaire does
not respect an IRT model. Therefore, additional work is in
progress to compare these methods on real data collected
from several clinical trials with various therapeutic
settings, cancer sites and designs. This comparison is
mandatory for the validation of the results obtained in the
present simulation study.
Each data set is different, and routinely using same
statistical analyses must be prevented in order to retain
an open and critical view. However, standardization of
longitudinal analysis of HRQoL data in oncology clinical
trials is essential in order to allow proper comparison of
results between trials. For example, two recent phase III
clinical trials investigating the impact of adding bevaci-
zumab to standard therapy in newly diagnosed glioblast-
oma, applied two different approaches (SM and TUDD)
to analyze longitudinal HRQoL data. The results are di-
vergent and compromise conclusions about the clinical
value of adding bevacizumab, since overall survival was
not improved [36,37]. To date, results from HRQoL stud-
ies have not been salient enough to lead to changes in
clinical practice. It is also necessary to provide decision-
makers with results that are clinical meaningful and easy
to understand [38]. In this context, the TTD/TUDD ap-
proach is attractive for clinicians, because it is based on
Kaplan–Meier survival curves and hazard ratios to qualify
effect size, as with other well-known and important time-
to-event outcomes in oncology (e.g. overall survival or
progression-free survival). However, this approach should
be used with caution in light of our results. Moreover, as
already shown for progression-free survival [39], the time
interval between assessments of HRQoL could influence
the Kaplan Meier estimation, thus resulting in an overesti-
mation of TUDD. Since the true time when HRQoL dete-
riorates may be unknown, dedicated statistic approaches
dealing with interval assessment may be proposed. It also
seems essential to properly study the profile of missing
data in advance, so as to propose a suitable method of
score imputation in case of intermittent missing items
with an MNAR profile. Some methods have to be devel-
oped for use in conjunction with the TTD, such as pattern
mixture models for SM model [40], in order to take into
account missing data with an MNAR profile. Survivalanalysis, such as the time to HRQoL score deterioration,
only gives unbiased results when censoring is independent
of the event. In oncology clinical trials, patients who have
a very low HRQoL level are more likely to drop out, and
thus the censure could be dependent on the event deteri-
oration. In this case, sensitivity analysis should be per-
formed considering patients who dropped out before the
planned end of the study as an event.
All-cause death is usually taken into account as an event,
particularly in an advanced setting [18]. However, death
was not integrated into our simulation algorithm, which
may explain in part the low statistical power of the TTD
approach. Moreover, one advantage of this method com-
pared to the mixed models is its adaptability to different
therapeutic settings (adjuvant or advanced settings) with
consideration of a transient or definitive deterioration, and
with or without integration of death as an event.
In conclusion, the SM model was clearly the most ef-
fective method, although the nature of the raw data in the
questionnaire means that the application of SM models in
this context remains open to criticism. The TTD/TUDD
approach, which is often used in the longitudinal analysis
of HRQoL in oncology, should be used with caution on
single-item dimensions of the EORTC questionnaires. Fi-
nally, while the LPCM was more adapted to this type of
data, it was ultimately difficult to implement and less effi-
cient than the SM model.
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